Providers also had an increase in comfort with new and effective adjuvant therapy for type 2 diabetes including SGLT2 inhibitors and GLP-1 agonist which are associated with a decrease in micro- and macro-vascular complications. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.